Search research articles
Contact Us
Filters
Showing results (91-100 of 101) with videos related to
Page
of 11
Sort By:
Biochemical Society Transactions
|
February 1, 1993
Polarity development and synaptogenesis in low density primary cultures of neocortex. Use of herpes simplex virus-1 vectors to transfer genes into postmitotic neurons
P R Lowenstein, E Morrison, P Hodge, et al.
Gynecologic Oncology
|
June 30, 2010
A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer
Michael Friedlander, Kenneth C Hancock, Danny Rischin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 17, 2001
Evaluation of the combination of nelarabine and fludarabine in leukemias: clinical response, pharmacokinetics, and pharmacodynamics in leukemia cells
V Gandhi, W Plunkett, S Weller, et al.
Investigational New Drugs
|
January 14, 2010
A phase I study of ispinesib, a kinesin spindle protein inhibitor, administered weekly for three consecutive weeks of a 28-day cycle in patients with solid tumors
Howard A Burris, Suzanne F Jones, Daphne D Williams, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 12, 2011
Phase I dose-finding study of pazopanib in hepatocellular carcinoma: evaluation of early efficacy, pharmacokinetics, and pharmacodynamics
Thomas Yau, Pei-Jer Chen, Pierre Chan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 24, 2005
Phase I study of 506U78 administered on a consecutive 5-day schedule in children and adults with refractory hematologic malignancies
J Kurtzberg, T J Ernst, M J Keating, et al.
Clinical Pharmacology and Therapeutics
|
October 29, 2010
A phase I study of the pharmacokinetic and safety profiles of oral pazopanib with a high-fat or low-fat meal in patients with advanced solid tumors
E I Heath, E G Chiorean, C J Sweeney, et al.
Cancer Chemotherapy and Pharmacology
|
May 13, 2010
A first in human study of SB-743921, a kinesin spindle protein inhibitor, to determine pharmacokinetics, biologic effects and establish a recommended phase II dose
Kyle D Holen, Chandra P Belani, George Wilding, et al.
The Oncologist
|
December 15, 2010
Phase I study of pazopanib in combination with weekly paclitaxel in patients with advanced solid tumors
Antoinette R Tan, Afshin Dowlati, Suzanne F Jones, et al.
Clinical Pharmacology and Therapeutics
|
October 1, 2010
An evaluation of the drug interaction potential of pazopanib, an oral vascular endothelial growth factor receptor tyrosine kinase inhibitor, using a modified Cooperstown 5+1 cocktail in patients with advanced solid tumors
B C Goh, N J Reddy, U B Dandamudi, et al.
Page
of 11
Search research articles
Search
Showing results (91-100 of 101) with videos related to
Sort By:
Page
of 11
Biochemical Society Transactions
|
February 1, 1993
Polarity development and synaptogenesis in low density primary cultures of neocortex. Use of herpes simplex virus-1 vectors to transfer genes into postmitotic neurons
P R Lowenstein, E Morrison, P Hodge, et al.
Gynecologic Oncology
|
June 30, 2010
A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer
Michael Friedlander, Kenneth C Hancock, Danny Rischin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 17, 2001
Evaluation of the combination of nelarabine and fludarabine in leukemias: clinical response, pharmacokinetics, and pharmacodynamics in leukemia cells
V Gandhi, W Plunkett, S Weller, et al.
Investigational New Drugs
|
January 14, 2010
A phase I study of ispinesib, a kinesin spindle protein inhibitor, administered weekly for three consecutive weeks of a 28-day cycle in patients with solid tumors
Howard A Burris, Suzanne F Jones, Daphne D Williams, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 12, 2011
Phase I dose-finding study of pazopanib in hepatocellular carcinoma: evaluation of early efficacy, pharmacokinetics, and pharmacodynamics
Thomas Yau, Pei-Jer Chen, Pierre Chan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 24, 2005
Phase I study of 506U78 administered on a consecutive 5-day schedule in children and adults with refractory hematologic malignancies
J Kurtzberg, T J Ernst, M J Keating, et al.
Clinical Pharmacology and Therapeutics
|
October 29, 2010
A phase I study of the pharmacokinetic and safety profiles of oral pazopanib with a high-fat or low-fat meal in patients with advanced solid tumors
E I Heath, E G Chiorean, C J Sweeney, et al.
Cancer Chemotherapy and Pharmacology
|
May 13, 2010
A first in human study of SB-743921, a kinesin spindle protein inhibitor, to determine pharmacokinetics, biologic effects and establish a recommended phase II dose
Kyle D Holen, Chandra P Belani, George Wilding, et al.
The Oncologist
|
December 15, 2010
Phase I study of pazopanib in combination with weekly paclitaxel in patients with advanced solid tumors
Antoinette R Tan, Afshin Dowlati, Suzanne F Jones, et al.
Clinical Pharmacology and Therapeutics
|
October 1, 2010
An evaluation of the drug interaction potential of pazopanib, an oral vascular endothelial growth factor receptor tyrosine kinase inhibitor, using a modified Cooperstown 5+1 cocktail in patients with advanced solid tumors
B C Goh, N J Reddy, U B Dandamudi, et al.
Page
of 11